Perioperative Chemoimmunotherapy With Durvalumab for Muscle-Invasive Urothelial Carcinoma: Primary Analysis of the Single-Arm Phase II Trial SAKK 06/17
Contributors
Cathomas, RichardPublished in
Journal of clinical oncology, vol. 41, no. 33, p. 5131-5139Publication date
2023-11-20First online date
2023-08-17Abstract
Keywords
- Humans
- Urinary Bladder Neoplasms / drug therapy
- Urinary Bladder Neoplasms / surgery
- Carcinoma, Transitional Cell / drug therapy
- Carcinoma, Transitional Cell / surgery
- Cisplatin / adverse effects
- Deoxycytidine / adverse effects
- Muscles
- Immunotherapy
- Antineoplastic Combined Chemotherapy Protocols / adverse effects
- Neoadjuvant Therapy / adverse effects
UNIGE affiliation entities
UNIGE research groups
Citation (ISO format)
CATHOMAS, Richard et al. Perioperative Chemoimmunotherapy With Durvalumab for Muscle-Invasive Urothelial Carcinoma: Primary Analysis of the Single-Arm Phase II Trial SAKK 06/17. In: Journal of clinical oncology, 2023, vol. 41, n° 33, p. 5131–5139. doi: 10.1200/JCO.23.00363
Main files (1)
Article (Published version)
Identifiers
- PID : unige:175804
- DOI : 10.1200/JCO.23.00363
- PMID : 37590894
- PMCID : PMC10666980
